Oncopeptides Q1 sales jump 91% on demand for Pepaxti in Italy

Oncopeptides AB

13/05/2026 07:09

Overview

Sweden biotech firm's Q1 net sales rose 91% yr/yr, driven by Pepaxti demand in Italy and Germany

Q1 operating and net losses narrowed from prior year

Company announced SEK 200 mln rights issue to fund operations and development

Outlook

Oncopeptides expects to reach country-level profitability in Germany during 2026

Company intends to expand Pepaxti label to third-line treatment, potentially doubling addressable patients

Oncopeptides expects positive cash flow in 2027, supported by SEK 200 mln rights issue

Result Drivers

ITALY DEMAND - Co said continued strong demand for Pepaxti in Italy drove sales, with the commercial launch exceeding expectations

GERMANY GROWTH - Co reported a return to solid growth in Germany, supported by a new business model and increased new patient numbers

SPAIN CHALLENGES - Co said sales in Spain were below expectations due to a doctors' strike, leading to more competition and less access to physicians

Company press release: ID:nMFN2jV6RS

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 25.38 mln
Q1 Adjusted EPS
-SEK 0.12
Q1 Net Income
-SEK 32.19 mln
Q1 Adjusted Free Cash Flow
-SEK 45.59 mln
Q1 Operating Profit
-SEK 37.53 mln


Analyst Coverage

Wall Street's median 12-month price target for Oncopeptides AB is SEK2.64, about 107% above its May 12 closing price of SEK1.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)